Compare Gilead Sciences, Inc. (GILD) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Gartner Inc — how do they compare? Gilead Sciences, Inc. trades at $133.02 (market cap $163.51B), while Gartner Inc trades at $138.45 (market cap $8.96B). The key difference: Gilead Sciences, Inc. is far larger — about 18.2× Gartner Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| GILD | IT | |
|---|---|---|
Market Cap | $163.51B | $8.96B |
Sector | Health | Technology |
52-Week High | $155.80 | $363.58 |
52-Week Low | $108.22 | $125.68 |
Enterprise Value | $178.05B | $10.55B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Gartner (IT) trades at $136.24, up 2.46% today, with a bearish technical signal but strong fundamentals including a 13.22 P/E ratio and consistent earnings beats. Revenue grew to $6.5B in 2025, though net income fell to $729M. Recent news highlights ongoing legal investigations and the company's influential role in tech research, with multiple firms named in Gartner reports.
The stock presents a mixed outlook: valuation metrics are attractive and analyst consensus targets $157.60, but technical weakness and legal overhangs pose near-term risks. Earnings momentum remains a key catalyst, though investor sentiment is cautious amid competition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
